A Multicenter Randomized Controlled Study on Pharmacokinetic‐Guided Vancomycin Use in Children With Severe Infections

ABSTRACT This study is a multicenter, randomized controlled prospective trial aimed at evaluating the effects of two vancomycin pharmacokinetics/pharmacodynamics (PK/PD) parameters on clinical outcomes in children with different severe infections: trough concentration (Cmin) and the area under the c...

Full description

Saved in:
Bibliographic Details
Main Authors: Fuxiang He, Ya Yang, Bo Zhou, Chengcheng Li, Yu Feng, Xuexin Wang, Haifeng Liu, Yuhang Hu, Hongmin Fu, Yingbo Zou, Guoying Zhang, Jianli Chen, Yueqiang Fu, Shufang Xiao, Lan Hu, Chengjun Liu
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Clinical and Translational Science
Subjects:
Online Access:https://doi.org/10.1111/cts.70309
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT This study is a multicenter, randomized controlled prospective trial aimed at evaluating the effects of two vancomycin pharmacokinetics/pharmacodynamics (PK/PD) parameters on clinical outcomes in children with different severe infections: trough concentration (Cmin) and the area under the curve (AUC0‐24/MIC). From January 2023 to December 2024, 472 pediatric patients from seven hospitals in Southwest China were included in the present study. These patients were randomly assigned to the AUC0‐24/MIC group or the Cmin group. After excluding 75 patients with renal function impairment caused by the primary disease, three patients with incomplete data, and one patient who received vancomycin for less than 48 h, 393 patients were finally enrolled for the present study. Then, the vancomycin treatment for children was evaluated using two PK/PD parameters, to guide clinical efficacy and monitor the incidence of adverse reactions: AUC0‐24/MIC, with a target value of 400–600 mg·h/L; trough concentration (Cmin), with a target value of 5–15 mg/L. The results indicated that there were no significant differences between the two groups in terms of daily dose, clinical efficacy, and adverse reactions. However, patients in the Cmin group had significantly shorter pediatric intensive care unit (PICU) stays (Z = −2.05, p = 0.04), and patients in the 28‐day to 1‐year‐old subgroup had shorter mechanical ventilation times (Z = −2.25, p = 0.024). Both Cmin and AUC0‐24/MIC were effective in guiding the vancomycin treatment for children with severe infections. However, patients in the Cmin group presented with advantages in PICU stay and ventilation duration. Trial Registration: China Clinical Trial Registry: ChiCTR2300067373
ISSN:1752-8054
1752-8062